Current treatment of osteosarcoma

Cancer Investigation

Volumn 19, Issue 3, 2001, Pages 292-315

  Ferguson, W S ^a   Goorin, A M ^a  

^a RHODE ISLAND HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BIOLOGICAL RESPONSE MODIFIER; BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MELPHALAN; METHOTREXATE; VINCRISTINE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; HUMAN; MULTIMODALITY CANCER THERAPY; OSTEOSARCOMA; POSTOPERATIVE CARE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL;

EID: 0035033404     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1081/CNV-100102557     Document Type: Article

References (310)

1. Osteogenic sarcoma under the age of twenty-one: A review of one hundred forty-five operative cases
2. MR imaging based strategies in limb salvage surgery for osteosarcoma of the distal femur
3. Scintigraphically negative skip metastasis in osteosarcoma
4. Tumors about the knee in children
5. Risk factors for local recurrences after limb-salvage surgery for high-grade osteosarcoma of the extremities
6. The effect of biopsy on survival of patients with osteosarcoma
7. The hazards of biopsy in patients with malignant primary bone and soft-tissue tumors
8. The hazards of the biopsy, revisited
9. Local relapses following limb sparing salvage surgery for osteosarcoma. Prognostic factors and influence of chemotherapy
10. Prognostic factors in osteosarcoma. A review of 20 years' experience ar the university of pittsburgh health center hospitals
11. Primary osteosarcoma of bone. Clinicopathologic investigation of 243 cases, with necropsy studies in 54
12. Weekly high-dose methotrexate and doxorubicin for osteosarcoma: The dana-farber cancer institute/the children's hospital - Study III
13. Effect of cumulative courses of intraarterial cis-diamminedichloroplatin-II on the primary tumor in osteosarcoma
14. Pediatric osteosarcoma: Therapeutic strategies, results, and prognostic factors derived from a 10-year experience
15. Increased survival, limb preservation, and prognostic factors for osteosarcoma
16. Therapy-induced changes in osteosarcoma after neoadjuvant chemotherapy (coss 86 therapy study). Correlation between morphologic findings and clinical follow-up
17. Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: Study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin
18. The Surgical Treatment of Patients with Osteosarcoma Who Sustain a Pathologic Fracture
19. Telangiectatic osteogenic sarcoma. Improved survival with combination chemotherapy
20. Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for telangiectatic osteogenic sarcoma of the extremities
21. Telangiectatic osteogenic sarcoma of the extremities. Results in 17 patients treated with neoadjuvant chemotherapy
22. Primary chemotherapy and delayed surgery for non-metastatic telangiectatic osteosarcoma of the extremities. Results in 28 patients
23. Osteosarcoma with small cells simulating ewing's tumor
24. Small-cell osteosarcoma
25. Small cell osteosarcoma. A clinicopathologic study of 27 cases
26. Small Cell Osteosarcoma of Bone. Review of 72 Cases
27. Neoadjuvant Chemotherapy for Osseous Malignant Fibrous Histiocy- toma of the Extremity: Results in 18 Cases and Comparison with 112 Contemporary Osteosarcoma Patients Treated with the Same Chemotherapy Regimen
28. Neoadjuvant chemotherapy in malignant fibrous histiocytoma of bone and in osteosarcoma located in the extremities: Analogies and differences between the two tumors
29. Preoperative intraarterial cisplatin based chemotherapy in the management of periosteal osteosarcoma
30. Conventional and dedifferentiated parosteal osteosarcoma. Diagnosis, treatment, and outcome
31. The metastatic patterns of osteosarcoma
32. Results of cytostatic therapy with cyclophosphamide, vincristine, adriamycin and DTIC (CYVADIC) in localized and metastasized osteosarcoma. A retrospective analysis
33. Adjuvant chemotherapy for osteosarcoma
34. Etoposide, cyclophosphamide, cisplatin,and doxorubicin as neoadjuvant chemotherapy for osteosarcoma
35. Primary chemotherapy and delayed surgery for osteosarcoma of the extremities with synchronous metastases
36. Osteosarcoma of the extremity metastatic at presentation: Results achieved in 26 patients treated with combined therapy (primary chemotherapy followed by simultaneous resection of the primary and metastatic lesions)
37. Osteosarcoma of the extremities metastatic at presentation. Results obtained with primary chemotherapy followed by simultaneous resection of the primary and metastatic lesion
38. Osteogenic sarcoma with clinically detectable metastasis at initial presentation
39. Osteogenic sarcoma of the extremity with detectable lung metastases at presentation. Results of treatment of 23 patients with chemotherapy followed by simultaneous resection of primary and metastatic lesions
40. Osteosarcoma of the extremities with synchronous lung metastases: Long-term results in 44 patients treated with neoadjuvant chemotherapy
41. Osteosarcoma: Fifteen years later
42. Video-assisted thoracic surgery (VATS) for children with pulmonary metastases from osteosarcoma
43. Prognostic significance of complete surgical resection of pulmonary metastases in patients with osteogenic sarcoma: Analysis of 32 patients
44. Thoracotomy for pulmonary metastatic osteosarcoma. An analysis of prognostic indicators of survival
45. Cooperative osteosarcoma study coss-77: Results after 4 years
46. Osteosarcoma chemotherapy effect: A prognostic factor
47. Neoadjuvant chemotherapy of osteosarcoma. Results of the cooperative studies COSS-80 and COSS-82 after 7 and 5 years
48. Intra-arterial cisplatin given prior to surgery in osteosarcoma: Grade of necrosis and size of tumor as major prognostic factors
49. Intraarterial cisplatin in the management of stage IIB osteosarcoma in the pediatric and adolescent age group
50. The prognostic significance of tumor volume in osteosarcoma with neoadjuvant chemotherapy
51. Tumor size and prognosis in aggressively treated osteosarcoma
52. Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the multi-institutional osteosarcoma study
53. Survival, prognosis, and therapeutic response in osteogenic sarcoma. The memorial hospital experience
54. Treatment of Nonmetastatic Osteosarcoma of the Extremity with Preoperative and Postoperative Chemotherapy: A Report from the Children's Cancer Group
55. Extremity and non-extremity high-grade osteosarcoma - The norwegian radium hospital experience during the modern chemotherapy era
56. Treatment results of osteogenic sarcoma. An evaluation of 36 patients treated during 30-year period in south-western finland
57. Osteosarcoma of the jaw bones. Long-term follow up of 48 cases
58. Chemotherapy for nonmetastatic osteogenic sarcoma: The memorial sloan-kettering experience
59. Prognostic factors among 130 patients with osteosarcoma
60. Long-term follow-up and post-relapse survival in patients with non-metastatic osteosarcoma of the extremity treated with neoadjuvant chemotherapy
61. Prognostic significance of serum alkaline phosphatase measurements in patients with osteosarcoma treated with adjuvant or neoadjuvant chemotherapy
62. Adjuvant chemotherapy in nonmetastatic osteosarcoma: A southwest oncology group study
63. Neoadjuvant chemotherapy in the treatment of osteosarcoma of the extremities: Preliminary results in 131 cases treated preoperatively with methotrexate and cisdiamminoplatinum
64. Clinical importance of near-diploid tumor stem lines in patients with osteosarcoma of an extremity
65. Loss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma
66. Heat shock protein 72 expression in osteosarcomas correlates with good response to neoadjuvant chemotherapy
67. ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma
68. Osteogenic sarcoma: The past, present, and future
69. Chemotherapy of osteosarcoma
70. Multiple-drug chemotherapy for the primary treatment of osteosarcoma of the extremities
71. Combination chemotherapy in osteogenic sarcoma: The memorial sloan-kettering cancer center experience
72. Multidrug chemotherapy in osteosarcoma
73. Adjuvant adriamycin and cis-diamminedichloroplatinum (cis-platinum) in primary osteosarcoma
74. High-dose methotrexate in osteogenic sarcoma adjuvant chemotherapy and limb salvage results
75. UK and european trials of chemotherapy in osteosarcoma
76. High-dose methotrexate and adriamycin in osteogenic sarcoma: The children's hospital of philadelphia study
77. Improved three-year disease-free survival in osteogenic sarcoma
78. Primary osteogenic sarcoma: Eight-year experience with adjuvant chemotherapy
79. Primary osteogenic sarcoma of the femur: A model for the use of preoperative chemotherapy in high risk malignant tumors
80. Adjuvant chemotherapy for osteosarcoma of the extrernity. Long-term results of two consecutive prospective protocol studies
81. Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma
82. The dana farber cancer institute/the children's hospital adjuvant chemotherapy trials for osteosarcoma: Three sequential studies
83. Adjuvant chemotherapy for osteogenic sarcoma
84. Osteogenic sarcoma: Alterations in the pattern of pulmonary metastases with adjuvant chemotherapy
85. Changing pattern of relapse in osteosarcoma of the extremities treated with adjuvant and neoadjuvant chemotherapy
86. Changing pattern of pulmonary metastases with adjuvant chemotherapy in patients with osteosarcoma: Results from the multiinstitutional osteosarcoma study
87. A controlled pilot study of high-dose methotrexate as postsurgical adjuvant treatment for primary osteosarcoma
88. Trends and variability in survival from osteosarcoma
89. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity
90. Adjuvant chemotherapy for osteosarcoma: A randomized prospective trial
91. Adriamycin-methotrexate high dose versus adriamycin-methotrexate moderate dose as adjuvant chemotherapy for osteosarcoma of the extremities: A randomized study
92. Changing pattern of relapses in osteosarcoma of the extremities (OE) treated with surgery alone (SA), or surgery in combination with adjuvant (AC) and neoadjuvant chemotherapy (NC)
93. Adjuvant chemotherapy with six drugs (adriamycin, methotrexate, cisplatinum, bleomycin, cyclophosphamide and dactinomycin) for non-metastatic high grade osteosarcoma of the extremities. Results of 32 patients and comparison to 127 patients concomitantly treated with the same drugs in a neoadjuvant form
94. Primary osteogenic sarcoma: The rationale for preoperative chemotherapy and delayed surgery
95. Results of the COSS-77 and COSS-80 studies on adjuvant chemotherapy in osteosarcoma of the extremities
96. Adjuvant adriamycin and cisplatin in newly diagnosed, nonmetastatic osteosarcoma of the extremity
97. Age and dose of chemotherapy as major prognostic factors in a trial of adjuvant therapy of osteosarcoma combining two alternating drug combinations and early prophylactic lung irradiation
98. Evaluation of adjuvant chemotherapy of osteosarcoma with special reference to adriamycin
99. Osteogenic sarcoma: Eighty eight-percent, three-year, disease-free survival with combination chemotherapy (T-7)
100. Preoperative (neoadjuvant) chemotherapy for osteogenic sarcoma: A ten year experience
101. Neoadjuvant chemotherapy for osteogenic sarcoma: A five year follow-up (T-10) and preliminary report of new studies (T-12)
102. Preoperative (neoadjuvant) chemotherapy for osteogenic sarcoma: A ten year experience
103. Long-term results of the co-operative german-austrian-swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs
104. IIB osteosarcoma. Current management, local control, and survival statistics - The Australian experience
105. Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate: A scandinavian sarcoma Group Study
106. The treatment of osteosarcoma: Present trends. The scandinavian sarcoma group experience
107. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin
108. Influence of adriamycin dose in the outcome of patients with osteosarcoma treated with multidrug neoadjuvant chemotherapy: Results of two sequential studies
109. Adjuvant chemotherapy for non-metastatic osteosarcoma of the extremities in two New Zealand cancer centres
110. Experience with protocol T10 in the pediatric service at the gustave-roussy institute
111. Long term follow-up of high grade osteosarcoma (OGS) treated (TX'D) with preoperative ifosfamide (I), adriamycin (A) and high dose methotrexate (M) with cisplatinum (C) added postop for poor responders
112. Neoadjuvant chemotherapy for pediatric osteosarcoma patients
113. Intensification of preoperative chemotherapy for osteogenic sarcoma: Results of the memorial sloan-kettering (T12) protocol
114. Adjuvant chemotherapy in osteosarcoma - Effects of cisplatinum, BCD, and fibroblast interferon in sequential combination with HD-MTX and adriamycin. Preliminary results of the COSS 80 study
115. Neoadjuvant chemotherapy for osteogenic sarcoma: Results of a cooperative German/Austrian study
116. Neoadjuvant chemotherapy of osteosarcoma: Results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response
117. Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities. The istituto rizzoli experience in 127 patients treated preoperatively with intravenous methotrexate (high versus moderate doses) and intraarterial cisplatin
118. Neoadjuvant chemotherapy for high grade osteosarcoma of the extremities: Is a good response to preoperative treatment an indication to reduce postoperative chemotherapy?
119. A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: The first study of the european osteosarcoma intergroup
120. Randomized trial of two regimens of chemotherapy in operable osteosarcoma: A study of the european osteosarcoma intergroup
121. No evidence for improved event free survival (EFS) with presurgical chemotherapy (PRE) for non-metastatic extremity osteogenic sarcoma (OGS): Preliminary results of randomized pediatric oncology group (POG) trial 8651
122. High-dose ifosfamide in advanced osteosarcoma
123. Neoadjuvant chemotherapy of osteosarcoma. Preliminary results of the cooperative COSS-86 osteosarcoma study
124. Treatment of osteosarcoma with ifosfamide: Comparison of response in pediatric patients with recurrent disease versus patients previously untreated: A pediatric oncology group study
125. Treatment of Metastatic osteosarcoma at diagnosis. A pediatric oncology group study
126. Treatment of metastatic osteosarcoma at diagnosis: A pediatric oncology group study
127. Neoadjuvant chemotherapy for nonmetastatic osteosarcoma of the extremities
128. Treatment of newly diagnosed high grade osteosarcoma (OS) with ifosfamide (IFOS), adriamycin (ADR), and cisplatin (CDP) without high dose methotrexate
129. Ifosfamide (IFO) and etoposide (VP) in refractory or recurrent childhood osteosarcoma (OS). A phase II study of the french society of pediatric oncology (SFOP)
130. High-dose (HD) ifosfamide and etoposide +G-CSF in pretreated adults with ewing's sarcoma and osteosarcoma
131. Successful phase II trial of etoposide and high dose ifosfamide in newly diagnosed metastatic osteosarcoma: A pediatric onncology group trial (POG)
132. Ifosfamide and etoposide in childhood osteosarcoma. A phase ii study of the french society of paediatric oncology
133. Neoadjuvant chemotherapy for the treatment of osteosarcoma of the extremities: Excellent response of the primary tumor to preoperative treatment with methotrexate, cisplatin, adriamycin, and ifosfamide. Preliminary results
134. The effect of intra-arterial versus intravenous cisplatinum in the neoadjuvant treatment of osteosarcoma of the limbs: The experience at the rizzoli institute
135. Preoperative and postoperative chemotherapy of osteogenic sarcoma of the limbs in children
136. Bleomycin, cyclophosphamide, and dactinomycin in metastatic osteosarcoma: Lack of tumor regression in previously treated Patients
137. Bleomycin nodules mimicking metastatic osteogenic sarcoma
138. Nodular form of bleomycin-related pulmonary injury in patients with osteogenic sarcoma
139. Long-term pulmonary toxicity of multiagent chemotherapy including bleomycin and cyclophosphamide in osteosarcoma survivors
140. Response of osteogenic sarcoma to the combination of etoposide and cyclophosphamide as neoadjuvant chemotherapy
141. The use of ifosfamide, carboplatin, and etoposide in children with solid tumors
142. Ifosfamide/carboplatin/etoposide (ICE) for recurrent malignant solid tumors of childhood: A pediatric oncology group phase I/II study
143. Pilot study of relapsed osteosarcoma and brain tumor with ifosfamide, carboplatin and etoposide
144. Carboplatin in the treatment of newly-diagnosed metastatic or unresectable osteosarcoma: A pediatric oncology group study
145. Ifosfamide (IFOS) and carboplatin (CARBO) window therapy in pPreviously untreated osteosarcoma (OS)
146. Curative therapy for osteosarcoma without cisplatin - Preliminary results of SJCRH OS-91
147. Osteosarcoma: Intra-arterial treatment of the primary tumor with cis-diammine-dichloroplatinum II (CDP). Angiographic, pathologic, and pharmacologic Studies
148. Neoadjuvant chemotherapy for osteosarcoma of the extremities. Good response of the primary tumor after preoperative chemotherapy with high-dose methotrexate followed by cisplatinum and adriamycin. Preliminary results
149. Systemic doxorubicin and intraarterial cisplatin preoperative chemotherapy plus postoperative adjuvant chemotherapy in patients with osteosarcoma
150. Extremity osteosarcomas: Intraarterial chemotherapy and limb-sparing resection with 2-year follow-up
151. Neoadjuvant chemotherapy for the treatment of osteosarcoma of the limbs. Preliminary results in 100 patients treated preoperatively with high doses of methotrexate i.V. Followed by cisplatin (i.a.) and adriamycin
152. Effect of intra-arterial versus intravenous cisplatin in addition to systemic adriamycin and high-dose methotrexate on histologic tumor response of osteosarcoma of the extremities
153. Intra-arterial versus intravenous cisplatinum (in addition to systemic adriamycin and high dose methotrexate) in the neoadjuvant treatment of osteosarcoma of the extremities. Results of a randomized study
154. Long term results of intra-arterial pre-operative chemotherapy for osteosarcoma
155. Effect of intraarterial versus intravenous cisplatin in addition to systemic doxorubicin, high-dose methotrexate, and ifosfamide on histologic tumor response in osteosarcoma (study COSS-86)
156. Pediatric osteosarcoma: Treatment of the primary tumor with intraarterial cis-diamminedichloroplatinum-II (CDP) - Advantages, disadvantages, and controversial issues
157. Intraarterial chemotherapy for osteosarcoma: Does the result really justify the effort?
158. Treatment of primary osteosarcoma with intra-arterial and intravenous high-dose methotrexate
159. Impact of two cycles of preoperative chemotherapy with intraarterial cisplatin and intravenous doxorubicin on the choice of surgical procedure for high-grade bone sarcomas of the extremities
160. Neoadjuvant chemotherapy for osteosarcoma of the extremity
161. Chemotherapy of osteosarcoma
162. Relationship of chemotherapy-induced necrosis and surgical margins to local recurrence in osteosarcoma
163. Prognostic factors in the response of primary osteogenic sarcoma to preoperative chemotherapy (high-dose methotrexate with citrovorum factor)
164. Zurich experience with preoperative, high dose methotrexate-containing chemotherapy in patients with extremity osteosarcomas (OSA)
165. Local control and survival from the cooperative osteosarcoma study group studies of the german society of pediatric oncology and the vienna bone tumor registry
166. Preoperative chemotherapy for osteosarcoma with intravenous adriamycin and intra-arterial cis-platinum
167. Disparate histologic responses in simultaneously resected primary and metastatic osteosarcoma following intravenous neoadjuvant chemotherapy
168. Synchronous multifocal osteosarcoma: Results in twelve patients treated with neoadjuvant chemotherapy and simultaneous resection of all involved bones
169. Preoperative chemotherapy for osteogenic sarcoma: Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy
170. Treatment of osteosarcoma. Experience of the cooperative osteosarcoma study group (COSS)
171. The angiographic response of osteosarcoma following pre-operative chemotherapy
172. Can conventional radiographs be used to monitor the effect of neoadjuvant chemotherapy in patients with osteogenic sarcoma?
173. The value of computed tomographic measurements in osteosarcoma as a predictor of response to adjuvant chemotherapy
174. Osteosarcoma: Chemotherapy-induced changes at mr imaging
175. Thallium-201 scanning for the evaluation of osteosarcoma and soft-tissue sarcoma. A study of the evaluation and predictability of the histological response to chemotherapy
176. Quantitative evaluation of thallium-201 uptake in predicting chemotherapeutic response of osteosarcoma
177. Thallium-201 scintigraphy to assess effect of chemotherapy in osteosarcoma
178. Thallium-201 scintigraphy for the evaluation of tumor response to preoperative chemotherapy in patients with osteosarcoma
179. Thallium-201 spect in differentiating bone infarction from metastatic lesions in osteosarcoma
180. Factor analysis as a means of determining response to chemotherapy in patients with osteogenic sarcoma
181. Use of 99mTc-MIBI scintigraphy in the evaluation of the response of osteosarcoma to chemotherapy
182. Monitoring neovascularity as an indicator to response to chemotherapy in osteogenic and Ewing's Sarcoma using magnetic resonance angiography
183. Factor analysis of dynamic magnetic resonance imaging in predicting the response of osteosarcoma to chemotherapy
184. Osteosarcoma and Ewing's Sarcoma after neoadjuvant chemotherapy: Value of dynamic mr imaging in detecting viable tumor Before Surgery
185. Dynamic contrast-enhanced mr imaging evaluation of osteosarcoma response to neoadjuvant chemotherapy
186. Osteosarcoma after chemotherapy: Evaluation with contrast material-enhanced subtraction MR imaging
187. Treatment of high-grade bone sarcomas with neoadjuvant chemotherapy: The utility of sequential color doppler sonography in predicting histopathologic response
188. Osteosarcoma: Angiographic assessment of response to preoperative chemotherapy
189. 18flurodeoxyglucose [FDG] correlates with histologic response in children with osteosarcoma [OS] and Ewing Sarcoma [ES]
190. Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome
191. Analysis of P-Glycoprotein expression in osteosarcoma
192. Multidrug resistance and malignancy in human osteosarcoma
193. P-Glycoprotein expression: Critical determinant in the response to osteosarcoma chemotherapy
194. Experimental models for the study of drug resistance in osteosarcoma: P-Glycoprotein-positive, murine osteosarcoma cell lines
195. Treatment of metastatic osteosarcoma with verapamil, cyclosporine and chemotherapy. A case report
196. Experience with multi-agent chemotherapy for osteosarcoma. Improved outcome
197. The importance of dose-intensity in neoadjuvant chemotherapy of osteosarcoma: A retrospective analysis of high-dose methotrexate, cisplatinum and adriamycin used preoperatively
198. Current management, local management, and survival statistics of high-grade osteosarcoma. Experience in Japan
199. Phase II study of low-dose methotrexate in advanced osteosarcoma followed by escalation after disease progression: A study of the soft tissue and bone sarcoma group of the european organization for research on treatment of cancer
200. Serum Methotrexate (MTX) Concentrations and Prognosis in Patients with Osteosarcoma of the Extremities Treated with a Multidrug Neoadjuvant Regimen
201. The importance of dose intensity in preoperative chemotherapy for osteosarcoma - Retrospective analysis of a short intensive chemotherapy regimen preoperatively using high-dose methotrexate and cisplatinum
202. Dose escalation with pharmacokinetics monitoring in methotrexate chemotherapy of osteosarcoma
203. The importance of doxorubicin and methotrexate dose intensity in the chemotherapy of osteosarcoma
204. Influence of methotrexate dose intensity on outcome of patients with high grade osteogenic osteosarcoma. Analysis of the literature
205. Methotrexate serum concentration and histologic response to multi-agent primary chemotherapy for osteosarcoma of the limbs
206. Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's Sarcoma
207. Children and cancer. A perspective from the cancer therapy evaluation program, national cancer institute
208. Prognostic value of dose intensity of drugs in localized osteosarcoma treated by protocols excluding high-dose methotrexate. A literature analysis
209. Prognostic significance of chemotherapy dosage characteristics in children with osteogenic sarcoma
210. A phase I trial of etoposide (VP) and escalating doses of ifosfamide (IFOS) plus G-CSF in recurrent pediatric sarcomas
211. Salvage treatment with high-dose ifosfamide and surgery for osteosarcoma patients relapsed with lung metastases. Preliminary results
212. 6-Day continuous infusion of high-dose ifosfamide with bone marrow growth factors in advanced refractory malignancies
213. A Randomized trial of two regimens of chemotherapy in operable osteosarcoma: A study of the european osteosarcoma intergroup (EOI)
214. A preliminary report of neoadjuvant chemotherapy nsh-7 study in osteosarcoma: Preoperative salvage chemotherapy based on clinical tumor response and the use of granulocyte colony-stimulating factor
215. Effect of chemotherapy combined with caffeine for osteosarcoma
216. Caffeine-assisted chemotherapy and minimized tumor excision for nonmetastatic osteosarcoma
217. Treatment of osteogenic sarcoma. I. Effect of adjuvant high-dose methotrexate after amputation
218. Adjuvant therapy for nonmetastatic osteogenic sarcoma: An evaluation of transfer factor versus combination chemotherapy
219. Phase II study of liposomal muramyl tripeptide in osteosarcoma: The cytokine cascade and monocyte activation following administration
220. Influence of chemotherapy administration on monocyte activation by liposomal muramyl tripeptide phosphatidylethanolamine in children with osteosarcoma
221. Unique histologic changes in lung metastases of osteosarcoma patients following therapy with liposomal muramyl tripeptide (CGP 19835A lipid)
222. Liposome-encapsulated muramyl tripeptide: A new biologic response modifier for the treatment of osteosarcoma
223. Liposome-encapsulated mtp-pe: A novel biologic agent for cancer therapy
224. Combination therapy with ifosfamide and liposome-encapsulated muramyl tripeptide: Tolerability, toxicity, and immune stimulation
225. Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma
226. Osteocalcin promoter-based toxic gene therapy for the treatment of osteosarcoma in experimental models
227. Varicella-zoster virus thymidine kinase gene and antiherpetic pyrimidine nucleoside analogues in a combined gene/chemotherapy treatment for cancer
228. Chemogene therapy: Osteocalcin promoter-based suicide gene therapy in combination with methotrexate in a murine osteosarcoma model
229. Retroviral vector-mediated transfer of an antisense cyclin g1 construct inhibits osteosarcoma tumor growth in nude mice
230. Somatostatin analog RC-160 inhibits the growth of human osteosarcomas in nude mice
231. Inhibition of growth of human osteosarcomas by antagonists of growth hormone-releasing hormone
232. Efficacy of the angiogenesis inhibitor O-(Chloroacetyl-Carbamoyl)Fumagillol (AGM-1470) on osteosarcoma growth and lung metastasis in rats
233. Targeted delivery of antineoplastic agent to bone: Biodistribution studies of technetium-99m-labeled gem-bisphosphonate conjugate of methotrexate
234. B7-1-transfected tumor vaccine counteracts chemotherapy-induced immunosuppression and prolongs the survival of rats bearing highly metastatic osteosarcoma cells
235. Autocrine activity of TGFβ in murine osteosarcoma cell lines
236. HER2 monoclonal antibody in patients with HER2/neu-overexpessing metastatic breast cancer
237. Limb-salvage treatment versus amputation for osteosarcoma of the distal end of the femur
238. Local failure (LF) of osteosarcoma (OS): Risk factors and Prognosis. Results of the cooperative OS study group COSS
239. Local recurrence (L) in non-metastatic osteosarcoma of the extremities (OE) treated with neoadjuvant chemotherapy (NC) - The rizzoli experience
240. Stage IIB osteogenic sarcoma
241. Predictive factors for local recurrence in osteosarcoma: 540 patients with extremity tumors followed for minimum 2.5 Years after neoadjuvant chemotherapy
242. Can amputation be avoided in local recurrence after limb salvage for high grade osteosarcoma? A case report and a review of the literature
243. Limb salvage compared with amputation for osteosarcoma of the distal end of the femur. A long-term oncological, function, and quality-of-life study
244. Quality of life in osteosarcoma survivors
245. The surgical treatment and outcome of pathologic fractures in localized osteosarcoma
246. Pathologic fracture in osteosarcoma. Impact of chemotherapy on primary tumor and survival
247. Encapsulation around malignant bone tumors after preoperative adjuvant treatment
248. Osteosarcoma in Hong Kong
249. Improved results in osteogenic sarcoma 1973-79 vs. 1980-86: Analysis of results from a single center
250. The use of bone allografts for limb salvage in high-grade extremity osteosarcoma
251. Current status of allografting for bone tumors
252. Replacement of the proximal humerus in primary bone tumors
253. Long-term results of allograft replacement in the management of bone tumors
254. The outcome and functional results of diaphyseal endoprostheses after tumour excision
255. The results of transplantation of intercalary allografts after resection of tumors. A long-term follow-up study
256. Reconstruction for defects of the proximal part of the femur using allograft arthroplasty
257. Extendable tumour endoprostheses for the leg in children
258. Limb salvage in pediatric osteosarcoma: Complications of prosthetic replacement and duration of function
259. Osteoarticular allografts
260. Limb Salvage for osteosarcoma in the 1980s
261. Osteoarticular allografts for reconstruction after resection of a musculoskeletal tumor in the proximal end of the tibia
262. Fractures of allografts. Frequency, treatment, and end-results
263. Infection in bone allografts. Incidence, nature, and treatment
264. Microvascularized free fibular grafts for reconstruction of skeletal defects after tumor resection
265. Malignant humeral bone tumors in children: Excision and reconstruction with the use of rotated clavicle
266. Treatment of osteosarcoma of the distal femur by rotation-plasty
267. Rotation-plasty for childhood osteosarcoma of the distal part of the femur
268. Rotationplasty as a reconstructive operation after tumor resection
269. Rotationplasty for limb salvage in the treatment of malignant tumors at the knee. A follow-up study of seventy patients
270. Rotationplasty Semin
271. The role of radiation therapy in the treatment of osteosarcoma
272. Radiotherapy and surgery in 50 cases of osteosarcoma treated without adjuvant chemotherapy
273. Hypofractionated accelerated radiotherapy in osteogenic sarcoma
274. Prophylactic lung irradiation in the treatment of osteogenic sarcoma
275. Adjuvant whole-lung radiation with or without adriamycin treatment in osteogenic sarcoma
276. C prophylactic irradiation of the lungs to prevent development of pulmonary metastases in patients with osteosarcoma of the limbs
277. Adjuvant therapy of osteogenic osteosarcomas of the limb: Results of the s04 78 trial
278. A strategic adjuvant therapy of osteosarcoma
279. Postoperative whole lung irradiation with or without adriamycin in osteogenic sarcoma
280. Elective whole lung irradiation in the treatment of osteogenic sarcoma
281. Radiation treatment of Ewing's Sarcoma and osteogenic sarcoma
282. Local radiotherapy combined with systemic chemotherapy in 3 children with osteosarcoma of an extremity
283. Elective whole-lung irradiation in osteosarcoma treatment: Appearance of bilateral breast cancer in two long-term survivors
284. Effect of chemotherapy on survival of craniofacial osteosarcoma: A systematic review of 201 patients
285. Breast cancer in a man 30 years after radiation for metastatic osteogenic sarcoma
286. Pulmonary function tests after whole-lung irradiation and doxorubicin in patients with osteogenic sarcoma
287. Small-cell osteosarcoma: Correlation of in vitro and clinical radiation response
288. Combined radiosensitizer infusion and irradiation of osteogenic sarcomas
289. Primary treatment of pelvic osteosarcoma. Report of five cases
290. Locally challenging osteo- and chondrogenic tumors of the axial skeleton: Results of combined proton and photon radiation therapy using three-dimensional treatment planning
291. Successful treatment of spinal osteosarcoma with radiation and chemotherapy
292. A Phase I/II study of a hypoxic cell radiosensitizer ku-2285 in combination with intraoperative radiotherapy
293. Potential advantages of protons over conventional radiation beams for paraspinal tumours
294. The role of fast neutron therapy in unresectable pelvic osteosarcoma: Preliminary report
295. Osteosarcomas and adult soft tissue sarcomas: Is there a place for high let radiation therapy?
296. Radiotherapy of bone tumors. Analysis of a historic series and review of the literature
297. Primary treatment of large and massive adult sarcomas with iododeoxyuridine and aggressive hyperfractionated irradiation
298. Intraoperative radiotherapy in the multidisciplinary treatment of bone sarcomas in children and adolescents
299. Misonidazole with small dose fractions in ah experimental osteosarcoma
300. 153Sm-EDTMP. A new promising approach
301. Pronounced therapeutic effect of samarium 153-ethylenediaminetetramethylene phosphonate in ah orthotopic human osteosarcoma tibial tumor model
302. Inactivation of human osteosarcoma cells in vitro by 211at-TP-3 monoclonal antibody: Comparison with astatine-211-labeled bovine serum albumin, free astatine-211 and external-beam X rays
303. 211At-labelled monoclonal antibody
304. Treatment of osteogenic sarcoma. II. Aggressive resection of pulmonary metastases
305. Combined chemotherapy and surgery for pulmonary metastases from osteogenic sarcoma. Results of 10 years experience
306. Osteosarcoma and pulmonary metastases: 15-year experience from a single institution
307. Treatment of patients with metastatic osteogenic sarcoma: A report from the children's cancer study group
308. Osteosarcoma recurrences in pediatric patients previously treated with intensive chemotherapy
309. Can amputation be avoided in local recurrence after limb salvage for high grade osteosarcoma? A case report and a review of the literature